FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979336543> ?p ?o ?g. }

• W1979336543 endingPage "166" @default.
• W1979336543 startingPage "156" @default.
• W1979336543 abstract "Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) widely used for treatment of inflammatory arthritis. Recent experimental and clinical studies suggest that piroxicam, as well as other NSAIDs, may be useful for chemoprevention of colon cancer. While there is less information regarding NSAIDs for chemoprevention of urinary bladder malignancy, there are compelling data which suggest that this should be evaluated. A major effect of NSAIDs is inhibition of cyclooxygenase, the rate-limiting enzyme for conversion of arachidonic acid to important signal molecules, including prostaglandins, which profoundly affect cellular functions in many tissues. The initial enzyme reaction leading to formation of prostaglandin H can be accompanied by cooxidation of xenobiotics resulting in extrahepatic and local tissue production of reactive products which are carcinogenic. The end product prostaglandins, especially prostaglandin E2 (PGE2), are biological modifiers which can significantly affect cell proliferation and tumor growth. High levels of PGE2 stimulate growth of certain tumor cell lines while inhibition of prostaglandin synthesis with indomethacin or piroxicam can cause suppression. The mechanisms for this effect are unclear. Studies in cultured cells exposed to indomethacin show inhibition of G1-to-S phase progression of the cell cycle and a reduction in overall DNA synthesis. It is unclear whether this effect on cell growth results from some direct action of the NSAID or a reduction in prostaglandins or indirectly from modulation of important control signals, such as calcium flux. In addition to cyclooxygenase, NSAIDs can inhibit activity of other enzymes, including phosphodiesterases and cyclic GMP-AMP protein kinases, which may be central to cancer initiation and promotion. NSAIDs can also interfere with transmembrane ion fluxes and with cell-to-cell binding. Prostaglandins can modulate a variety of immunological responses and thereby play an important role in host antitumor immunity. For example, high levels of tissue PGE2 are frequently associated with suppression of immune surveillance and killing of malignant cells. Conversely, immune responses are generally enhanced by drugs that inhibit prostaglandin synthesis. PGE2 can act as a feedback inhibitor for cellular immune processes, such as T-cell proliferation, lymphokine production, and cytotoxicity. This effect is also seen for macrophage activity and natural killer cell toxicity. In general, either increased production of PGE2 or increased sensitivity to normal amounts of PGE2 results in depressed cellular immunity. Cyclooxygenase inhibitors (NSAIDs) such as piroxicam which decrease PGE2 production can stimulate cellular immune function both in vitro and in vivo. A variety of tumor cell lines and human malignancies produce large quantities of prostaglandins.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W1979336543 created "2016-06-24" @default.
• W1979336543 creator A5016748991 @default.
• W1979336543 creator A5029541691 @default.
• W1979336543 creator A5082229827 @default.
• W1979336543 date "1992-01-01" @default.
• W1979336543 modified "2023-09-23" @default.
• W1979336543 title "Piroxicam and other cyclooxygenase inhibitors: Potential for cancer chemoprevention" @default.
• W1979336543 cites W1659584317 @default.
• W1979336543 cites W1669371681 @default.
• W1979336543 cites W1710339702 @default.
• W1979336543 cites W1783022590 @default.
• W1979336543 cites W1969849186 @default.
• W1979336543 cites W1973577382 @default.
• W1979336543 cites W1974386988 @default.
• W1979336543 cites W1986439328 @default.
• W1979336543 cites W1995568029 @default.
• W1979336543 cites W1995978700 @default.
• W1979336543 cites W2001258296 @default.
• W1979336543 cites W2007796985 @default.
• W1979336543 cites W2009822380 @default.
• W1979336543 cites W2013066873 @default.
• W1979336543 cites W2013470548 @default.
• W1979336543 cites W2031652451 @default.
• W1979336543 cites W2038453831 @default.
• W1979336543 cites W2043539979 @default.
• W1979336543 cites W2045691345 @default.
• W1979336543 cites W2048680569 @default.
• W1979336543 cites W2057252291 @default.
• W1979336543 cites W2059340303 @default.
• W1979336543 cites W2059689162 @default.
• W1979336543 cites W2063293439 @default.
• W1979336543 cites W2065851152 @default.
• W1979336543 cites W2084678619 @default.
• W1979336543 cites W2122159614 @default.
• W1979336543 cites W2151088106 @default.
• W1979336543 cites W2167555569 @default.
• W1979336543 cites W2314690845 @default.
• W1979336543 cites W2317184681 @default.
• W1979336543 cites W2330709704 @default.
• W1979336543 cites W2400530759 @default.
• W1979336543 doi "https://doi.org/10.1002/jcb.240501330" @default.
• W1979336543 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1305681" @default.
• W1979336543 hasPublicationYear "1992" @default.
• W1979336543 type Work @default.
• W1979336543 sameAs 1979336543 @default.
• W1979336543 citedByCount "109" @default.
• W1979336543 countsByYear W19793365432012 @default.
• W1979336543 countsByYear W19793365432013 @default.
• W1979336543 countsByYear W19793365432015 @default.
• W1979336543 countsByYear W19793365432016 @default.
• W1979336543 countsByYear W19793365432018 @default.
• W1979336543 countsByYear W19793365432019 @default.
• W1979336543 countsByYear W19793365432020 @default.
• W1979336543 countsByYear W19793365432021 @default.
• W1979336543 countsByYear W19793365432022 @default.
• W1979336543 crossrefType "journal-article" @default.
• W1979336543 hasAuthorship W1979336543A5016748991 @default.
• W1979336543 hasAuthorship W1979336543A5029541691 @default.
• W1979336543 hasAuthorship W1979336543A5082229827 @default.
• W1979336543 hasConcept C142724271 @default.
• W1979336543 hasConcept C181199279 @default.
• W1979336543 hasConcept C185592680 @default.
• W1979336543 hasConcept C204787440 @default.
• W1979336543 hasConcept C2778139025 @default.
• W1979336543 hasConcept C2779689624 @default.
• W1979336543 hasConcept C2780664492 @default.
• W1979336543 hasConcept C502942594 @default.
• W1979336543 hasConcept C55493867 @default.
• W1979336543 hasConcept C62112901 @default.
• W1979336543 hasConcept C71924100 @default.
• W1979336543 hasConcept C98274493 @default.
• W1979336543 hasConceptScore W1979336543C142724271 @default.
• W1979336543 hasConceptScore W1979336543C181199279 @default.
• W1979336543 hasConceptScore W1979336543C185592680 @default.
• W1979336543 hasConceptScore W1979336543C204787440 @default.
• W1979336543 hasConceptScore W1979336543C2778139025 @default.
• W1979336543 hasConceptScore W1979336543C2779689624 @default.
• W1979336543 hasConceptScore W1979336543C2780664492 @default.
• W1979336543 hasConceptScore W1979336543C502942594 @default.
• W1979336543 hasConceptScore W1979336543C55493867 @default.
• W1979336543 hasConceptScore W1979336543C62112901 @default.
• W1979336543 hasConceptScore W1979336543C71924100 @default.
• W1979336543 hasConceptScore W1979336543C98274493 @default.
• W1979336543 hasIssue "S16I" @default.
• W1979336543 hasLocation W19793365431 @default.
• W1979336543 hasLocation W19793365432 @default.
• W1979336543 hasOpenAccess W1979336543 @default.
• W1979336543 hasPrimaryLocation W19793365431 @default.
• W1979336543 hasRelatedWork W1969053386 @default.
• W1979336543 hasRelatedWork W1980466497 @default.
• W1979336543 hasRelatedWork W2032043921 @default.
• W1979336543 hasRelatedWork W2056325903 @default.
• W1979336543 hasRelatedWork W2062176029 @default.
• W1979336543 hasRelatedWork W2085365609 @default.
• W1979336543 hasRelatedWork W2087224686 @default.
• W1979336543 hasRelatedWork W2122953993 @default.
• W1979336543 hasRelatedWork W2412996943 @default.

• next